[1]李园园,杜灵彬,王悠清,等.浙江省食管癌筛查的经济学评价——以生命年为效果指标[J].卫生经济研究,2022,39(3):18-23,27.
　LI Yuan-yuan,DU Ling-bin,WANG You-qing,et al.Economic Evaluation of Esophageal Cancer Screening in Zhejiang Province——Take Life Year as the Effect Index[J].Journal Press of Health Economics Research,2022,39(3):18-23,27.
点击复制

浙江省食管癌筛查的经济学评价
——以生命年为效果指标
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年3期
页码:
18-23,27
栏目:
疾病经济负担
出版日期:
2022-03-01

文章信息/Info

Title:
Economic Evaluation of Esophageal Cancer Screening in Zhejiang Province
——Take Life Year as the Effect Index
作者:
李园园1; 杜灵彬2; 王悠清2; 孙雪姗3; 顾玉璇3; 董恒进3
1.杭州市第九人民医院，浙江 杭州311225
2.浙江省癌症研究中心，中国科学院大学附属肿瘤医院，浙江 杭州 310022
3.浙江大学公共卫生学院卫生政策研究中心，浙江 杭州 310058
Author(s):
LI Yuan-yuan;  DU Ling-bin;  WANG You-qing;  SUN Xue-shan;  GU Yu-xuan;  DONG Heng-jin
Hangzhou Ninth People's Hospital, Hangzhou Zhejiang 311225, China
关键词:
食管癌; 筛查; 早诊早治; 成本效果分析; Markov模型
Keywords:
esophageal cancer;  screen;  early diagnosis and treatment;  cost-effect analysis;  Markov model
分类号:
R19
文献标志码:
B
摘要:
目的：评价浙江省食管癌筛查的经济学效果，明确适宜的筛查起始年龄。方法：根据食管癌进展史构建11个态状的Markov模型，将40~69岁人群分成6个年龄组，每个年龄组假设实施3种策略（筛查随访、筛查不随访、不筛查），以生命年为效果指标、增量成本效果比为经济学评价指标，使用敏感性分析验证模型的稳定性。结果：40~44岁和45~49岁年龄组，筛查随访是绝对优势策略，与不筛查相比，每获得1个生命年分别节约39 311.05元和15 247.88元；50~54岁年龄组，筛查随访具有成本有效性，与不筛查相比，每获得1个生命年的成本为59 661.45元。结论：40~54岁年龄组人群进行食管癌筛查具有成本有效性。
Abstract:
Objective To evaluate the economic effect of esophageal cancer screening in Zhejiang Province, and to determine the appropriate starting age for screening. Methods A Markov model with 11 states was constructed according to the progression history of esophageal cancer, and population aged between 40 and 69 was divided into 6 age groups. Each age group was assumed to implement 3 strategies (screening with follow-up, screening without follow-up, and no screening). Then this study took life year as the effect index and the incremental cost-effectiveness ratio as the economic evaluation index. Sensitivity analysis was used to verify the stability of the model. Results In the age groups of 40-44 years and 45-49 years old, screening with follow-up was an absolute superior strategy. Compared with no screening, it saved 39 311.05 yuan and 15 247.88 yuan for each life-year gained. While among 50-54 years old group, screening with follow-up was cost-effective. The cost per life-year gained was 59 661.45 yuan compared with no screening. Conclusion Esophageal cancer screening is cost-effective among people aged 40-54 years.

参考文献/References:

[1] 中国药学会药物经济学专业委员会.中国药物经济学评价指南2019 [S].2019.
[2] Miller DK,Homan SM.Determining transition probabilities: confusion and suggestions[J].Medical Decision Making:an international journal of the Society for Medical Decision Making，1994，14(1):52-58.
[3] Whang SJ,Zhang LW,Wen DG,et al.Analysis of Endoscopic Screening for the Natural History of Precancerous Lesions in Esophagus and Cardia[J].Chian cancer,2007,34(7):370-373.
[4] Wen D,Zhang L,Wang X,et al.A 5.5-year surveillance of esophageal and gastric cardia precursors after a population-based screening in China[J].Journal of gastroenterology and hepatology,2015,30(12): 1720-1725.
[5] Wen DG,Zhang LW,Wang XL, et al.Heterogeneity in esophageal and gastric cardia precursor progression during six-year endoscopic surveillance after population-based screening in a Chinese high-risk region[J].Thorac Cancer,2017,8(4):328-336.
[6] Chinese Academy of Medical Sciences, Esophageal Cancer Prevention and Treatment Research Team in Linxian.Outcome of Esophageal Epithelial Hyperplasia: Summary of Follow-up by Cytological Examinatio[J].Cancer Research on Prevention and Treatment,1974(1):42-46.
[7] He YL,Zhang WJ,Liu YQ.Analysis of Endoscopic Screening for Upper Digestive Tract Cancer in Gaotai County,2011-2015[J].China cancer, 2017,26(6):447-451.
[8] LH L.Analysis of Esophageal cancer/Cardia Cancer Screening with Iodine Staining Method throug Endoscopy and Esophageal atypical hyperplasia fellow-up in XianJu[Maser thesis][R].Zhejiang: Zhejiang University，2014.
[9] Wang LD,Guo HQ.The development of esophageal epithelial hyperplasia-six years’ follow-up of 66 subjects[J].Journal of Henan Medical University,1991,26(4):328-330.
[10] Nagami Y,Ominami M,Shiba M,et al.The five-year survival rate after endoscopic submucosal dissection for superficial esophageal squamous cell neoplasia[J].Dig Liver Dis,2017,49(4):427-433.
[11] Nakagawa K,Koike T,Iijima K,et al.Comparison of the long-term outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan[J].Am J Gastroenterol,2014,109(3):348-356.
[12] Yamashina T,Ishihara R,Nagai K, et al.Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma[J].Am J Gastroenterol,2013,108(4):544-551.
[13] Tsujii Y,Nishida T,Nishiyama O,et al. Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms:a multicenter retrospective cohort study[J].Endoscopy,2015, 47(9):775-783.
[14] Daoud DC,Suter N,Durand M, et al. Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries:A systematic review and meta-analysis[J].World J Gastroenterol，2018，24(23):2518-2536.
[15] Konda VJ,Ross AS,Ferguson MK, et al.Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?[J].Clinical gastroenterology and hepatology :the official clinical practice journal of the American Gastroenterological Association，2008，6(2):159-164.
[16] Rice TW,Lerut TE,Orringer MB,et al.Worldwide Esophageal Cancer Collaboration:neoadjuvant pathologic staging data[J].Dis Esophagus，2016，29(7):715-723.
[17] Gockel I,Sgourakis G,Lyros O, t al.Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients[J].Expert Rev Gastroenterol Hepatol，2011，5(3):371-384.
[18] Chan DS,Reid TD,Howell I,et al.Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer[J]. The British journal of surgery，2013，100(4):456-464.
[19] Chen SB,Weng HR,Wang G,et al.Surgical treatment for early esophageal squamous cell carcinoma[J].Asian Pac J Cancer Prev，2013，14(6):3825-3830.
[20] Fujita H,Sueyoshi S,Yamana H,et al.Optimum treatment strategyfor superficial esophageal cancer:endoscopic mucosal resection versus radical esophagectomy[J].World J Surg，2001，25(4):424-431.
[21] Stein HJ,Feith M,Mueller J,et al.Limited resection for early adenocarcinoma in Barrett's esophagus[J].Ann Surg，2000，232(6):733-742.
[22] Mitsuo Tachibana,Hiroshi Yoshimura,Shoichi Kinugasa,et al.Clinicopathological Features of Superficial Squamous Cell Carci noma of the Esophagus[J].Am J Surg，1997，174:49-53.
[23] van Sandick JW,van Lanschot JJ,ten Kate FJ,et al.Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making[J].Cancer，2000，88(11):2429-2437.
[24] Yoshinaka H,Shimazu H,Fukumoto T,et al.Superficial esophageal carcinoma:a clinicopathological review of 59 cases[J].Am J Gastroenterol，1991，86(10):1413-1418.
[25] Natsugoe S,Baba M,Yoshinaka H,et al.Mucosal squamous cell carcinoma of the esophagus:a clinicopathologic study of 30 cases[J].Oncology,1998,55(3):235-41.
[26] Sgourakis G,Gockel I,Lang H.Endoscopic and surgical resection of T1a/T1b esophageal neoplasms:a systematic review[J].World journal of gastroenterology，2013，19(9):1424-1437.
[27] Karstens KF,Izbicki JR,Reeh M.Does the Margin Matter in Esophageal Cancer[J].Digestive surgery，2018，35(3):196-203.
[28] Knight WRC,Zylstra J,Wulaningsih W,et al.Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma[J].BJS Open，2018，2(4):229-237.
[29] Zou ZH,Liao XZ,Xu KK, et al. Analysis of screening results of 6400 urban lung cancer in high-risk groups[J].Practical Preventive Medicine，2016，23(5):593-594.
[30] Saddoughi SA,Reinersman JM,Zhukov YO,et al.Survival After Surgical Resection of Stage IV Esophageal Cancer[J].Ann Thorac Surg，2017103(1):261-266.
[31] Wei WQ,Chen ZF,He YT,et al.Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China[J].J Clin Oncol，2015，33(17):1951-1957.
[32] Rice TW,Ishwaran H, Hofstetter WL,et al.Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals[J]. Dis Esophagus，2016，29(8):897-905.
[33] U.S.National cancer Institution.Cancer Stat Fact Sheets: Esophageal Cancer [EB/OL].http://seer.cancer.gov/statfacts/html/esoph.html.
[34] Chen ZL,Ren YH, Du XLL,et al.Incidence and survival differences in esophageal cancer among ethnic groups in the United States[J].Oncotarget，2017，8(29):47037-47051.
[35] 左婷婷,郑荣寿, 曾红梅, 等.中国食管癌发病状况与趋势分析[J].中华肿瘤杂志，2016，38（9）：703-708.
[36] Mao WM,Jin F,Yu M.Zhejiang Cancer Registry Annual Report[R].Zhejiang Science and Technology Press，2016.
[37] 冯昊.中国农村食管癌高发区终生一次内镜筛查适宜起始年龄研究[R].北京: 北京协和医学院中国医学科学院，清华大学医学部，2015.

更新日期/Last Update: 2022-03-01